Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics


Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Today's Latest Price: $12.32 USD

0.08 (-0.65%)

Updated Jan 26 7:00pm

Add TEVA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TEVA Stock Summary

  • Teva Pharmaceutical Industries Ltd's market capitalization of $13,590,047,294 is ahead of 85.42% of US-listed equities.
  • Teva Pharmaceutical Industries Ltd's stock had its IPO on March 26, 1990, making it an older stock than 84.18% of US equities in our set.
  • Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.72%, greater than the shareholder yield of 87.45% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Teva Pharmaceutical Industries Ltd are OC, IMO, ATO, CCL, and ASH.
  • Visit TEVA's SEC page to see the company's official filings. To visit the company's web site, go to www.tevapharm.com.

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $12.32 52-week high $13.76
Prev. close $12.40 52-week low $6.25
Day low $12.15 Volume 5,263,000
Day high $12.48 Avg. volume 10,929,600
50-day MA $10.45 Dividend yield N/A
200-day MA $10.62 Market Cap 13.46B

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio


Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.

TEVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$12.32$0.45 -96%

We started the process of determining a valid price forecast for Teva Pharmaceutical Industries Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Teva Pharmaceutical Industries Ltd, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is -4.72; that's higher than just 13.34% of US stocks in the Healthcare sector that have positive free cash flow.
  • The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than only 5.54% of US stocks we're applying DCF forecasting to.
  • 34% of the company's capital comes from equity, which is greater than only 10.22% of stocks in our cash flow based forecasting set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-96%
1%-96%
2%-96%
3%-96%
4%-96%
5%-96%

NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


TEVA Latest News Stream


Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream


Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about Teva Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Global Skeletal Complications Treatment Market Size | COVID-19 Impact Analysis | Forecast to 2028 | Cipla Inc., Regeneron Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., Teva Pharmaceutical Industries

Databridgemarketresearch.com Present “Skeletal Complications Treatment Market– Industry Trends and Forecast to 2027” new report to its research database. The report first introduces the market basics like definitions, classifications, applications and industry chain overview, and then industry policies and plans, product

OpenPR | January 25, 2021

Global Vitiligo Treatment Market Overview With Detailed Analysis, Competitive Landscape 2020-206||Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd

Vitiligo Treatment market report is an accurate study of the Pharmaceutical industry which gives estimations about new triumphs that will be made in the Vitiligo Treatment market in 2020-2026. It also explains what the market definition, classifications, applications, engagements, and

OpenPR | January 22, 2021

Parkinson’s Disease Therapeutic Market To Be Fuelled By Rapid Shift In Consumer Perception And Increasing Awareness | Salix Pharmaceuticals, Teva Pharmaceutical Industries Ltd.

Coherent Market Insights released a new market study on 2018-2026 “Parkinson’s Disease Therapeutic Market” with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy-to-understand detailed analysis. At present, the market is developing its presence. The

OpenPR | January 19, 2021

Global Eating Disorder Market 2021: Growth Rate And Recent Trends, Opportunities, Impact of Drivers, Key Vendors-Somerset Therapeutics, LLC, Mylan N.V., Teva Pharmaceuticals Industries Ltd

Eating disorder market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of mental

OpenPR | January 19, 2021

Global Acromegaly Market 2021: Future Prospects With Covid-19 Impact Analysis 2027 | Top Players- Novartis AG, Sun Pharmaceutical Industries Ltd, Mylan N.V., Teva Pharmaceutical Industries, Fresenius Kabi USA

The Report Titled on “Acromegaly Market Report-Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2020” firstly introduced the Acromegaly Industry basics: The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors.The report

OpenPR | January 18, 2021

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo 26.88%
3-mo 40.96%
6-mo 6.76%
1-year 20.67%
3-year -42.24%
5-year -78.89%
YTD 27.67%
2020 -1.53%
2019 -36.45%
2018 -18.63%
2017 -46.23%
2016 -43.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8865 seconds.